When?

22 April 2024
15:30 - 15:30

Where?

Online
Link will be provided by mail

Registration

Register here

Who?

Anyone interested in the topic in Denmark.

Background

In the context of metastatic cancers, decisions regarding systemic palliative therapies often rely on the Response Evaluation Criteria in Solid Tumors (RECIST). It is an imaging centric approach used as a key to treatment decisions. RECIST has its limitations and therefore, there is a need for refined tools in assessing treatment efficacy.

With Karen-Lise Garm Spindler in front, a network proposes an alternative - ctDNA-RECIST. This response classification system pivots on the measurements of circulating tumor DNA (ctDNA) and its confidence intervals. The intention is to ignite a dialogue around ctDNA-RECIST and its potential impact on clinical decision-making.

For deeper insights into the background of the propose of ctDNA-RECIST, we recommend exploring the following publications:

Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors - can we RECIST? Focus on colorectal cancer
Karen-Lise Garm Spindler, Anders Jacobsen
(2023, April). Therapeutic Advances in Medical Oncology, vol 15. Pages 1-11. Doi: 10.1177/17588359231171580

ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology
Anders K. M. Jakobsen, Karen-Lise Garm Spindler
(2023, February). European Journal of Cancer, 180. Pages 180-183. doi: 10.1016/j.ejca.2022.11.039. PMID: 36610263

Reporting on circulating tumor DNA monitoring in metastatic cancer-From clinical validity to clinical utility
Brenner Thomsen C, Dandanell Juul A, Lefèvre AC, Glismand Truelsen C, Dizdarevic E, Ryssel H, Mathilde Kjaer I, Lycke Wind K, Callesen LB, Faaborg Larsen L, Støchkel Frank M, Fredslund Andersen R, Garm Spindler KL, and Jakobsen A.
 Cancer. 2022 Jun 1;128(11):2052-2057. doi: 10.1002/cncr.34168. Epub 2022 Mar 18. PMID: 35302663.

The webinar

We invite you to this webinar, where we will focus on ctDNA-RECIST and the potentials to redefine how we measure treatment response and tailor interventions for cancer patients.

Karen-Lise Garm Spindler will lead the webinar, and we will discuss:

• What is RECIST, and its short comings?
• Challenges in defining ctDNA response evaluation criteria
• The ctDNA RECIST principles
• The potential clinical impact of ctDNA-RECIST
• Status of the ctDNA program and international context
• Discussion

We look forward to welcoming you to this webinar!

Webinar leader

ADDRESS FOR THE SECRETARIAT

Science Center Skejby, MOMA
Brendstrupgårdsvej 21, build. A
8200 Aarhus N

CONTACT

ctDNA@clin.au.dk
+45 78 45 53 39